晚期肝细胞癌的抗程序性死亡-1治疗：一项真实世界经验
Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.
作者信息
Al Jarroudi Ouissam, Chaabouni Hamed, Ulusakarya Ayhan, Almohamad Wathek, Gumus Yusuf, Goldschmidt Emma, Afqir Said, Morère Jean-Francois
机构信息
Medical Oncology Department AP-HP Paul Brousse Hospital Villejuif France.
Medical Oncology Department University Hospital Mohammed VI-Oujda Oujda Morocco.
出版信息
Clin Case Rep. 2021 Feb 20;9(4):2162-2167. doi: 10.1002/ccr3.3970. eCollection 2021 Apr.
Abstract
Nivolumab is an effective and safe treatment in HCC.
摘要
纳武利尤单抗是一种治疗肝癌有效且安全的疗法。
相似文献
1
Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.晚期肝细胞癌的抗程序性死亡-1治疗：一项真实世界经验
Clin Case Rep. 2021 Feb 20;9(4):2162-2167. doi: 10.1002/ccr3.3970. eCollection 2021 Apr.
2
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.纳武利尤单抗与帕博利珠单抗在不可切除肝细胞癌患者中的真实世界疗效比较
Pharmaceutics. 2022 Oct 23;14(11):2263. doi: 10.3390/pharmaceutics14112263.
3
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.纳武利尤单抗治疗晚期肝细胞癌患者的炎症生物标志物与临床结局的关系。
J Hepatol. 2020 Dec;73(6):1460-1469. doi: 10.1016/j.jhep.2020.07.026. Epub 2020 Jul 22.
4
A Real-World Experience on a Chinese Population of Patients With Unresectable Hepatocellular Carcinoma Treated With Nivolumab.纳武单抗治疗中国不可切除肝细胞癌患者的真实世界经验
Gastroenterology Res. 2024 Feb;17(1):15-22. doi: 10.14740/gr1684. Epub 2024 Feb 28.
5
Nivolumab for the treatment of hepatocellular carcinoma.纳武利尤单抗治疗肝细胞癌。
Expert Opin Biol Ther. 2020 Jul;20(7):687-693. doi: 10.1080/14712598.2020.1749593. Epub 2020 Apr 20.
6
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.纳武利尤单抗在晚期肝细胞癌中的注册后经验：一项国际研究。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-001033.
7
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.程序性死亡受体 1（PD-1）靶向免疫疗法治疗晚期肝细胞癌：来自国际多中心真实世界队列的疗效和安全性数据。
Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.
8
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.卡博替尼和纳武利尤单抗治疗 RET 扩增、高肿瘤突变负荷和 PD-L1 表达的肝细胞癌的疗效。
Oncologist. 2020 Jun;25(6):470-474. doi: 10.1634/theoncologist.2019-0563. Epub 2020 Feb 26.
9
Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World.程序性细胞死亡蛋白1（PD-1）靶向免疫疗法在真实世界中治疗晚期肝细胞癌的应用
Onco Targets Ther. 2020 Jan 8;13:143-149. doi: 10.2147/OTT.S234868. eCollection 2020.
10
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.肝动脉灌注化疗联合抗PD-1免疫疗法及酪氨酸激酶抑制剂治疗晚期肝细胞癌的真实世界研究
Immunotherapy. 2021 Dec;13(17):1395-1405. doi: 10.2217/imt-2021-0192. Epub 2021 Oct 5.
本文引用的文献
1
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.肝细胞癌的免疫治疗：最新进展与未来展望
Ther Adv Med Oncol. 2019 Jul 23;11:1758835919862692. doi: 10.1177/1758835919862692. eCollection 2019.
2
Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma.雷莫西尤单抗作为肝细胞癌的二线全身治疗
Liver Cancer. 2018 Oct;7(4):305-311. doi: 10.1159/000492534. Epub 2018 Aug 23.
3
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.肝细胞癌的全身治疗：最新进展
Cancers (Basel). 2018 Oct 30;10(11):412. doi: 10.3390/cancers10110412.
4
Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.纳武利尤单抗治疗晚期肝细胞癌的可行性和安全性：来自三个德国中心的真实世界经验。
J Cancer Res Clin Oncol. 2019 Jan;145(1):253-259. doi: 10.1007/s00432-018-2780-8. Epub 2018 Oct 29.
5
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
6
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.肝细胞癌的免疫治疗：当前进展与未来展望。
J Immunol Res. 2018 Mar 26;2018:8740976. doi: 10.1155/2018/8740976. eCollection 2018.
7
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
8
ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function.ALBI评分作为肝细胞癌分期和治疗规划的新工具：ALBI分级在肝功能通用评估中的优势
Liver Cancer. 2017 Nov;6(4):377-379. doi: 10.1159/000481212. Epub 2017 Oct 19.
9
Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma.纳武单抗抗PD1疗法治疗晚期肝细胞癌的初步经验。
Oncotarget. 2017 Aug 8;8(57):96649-96655. doi: 10.18632/oncotarget.20029. eCollection 2017 Nov 14.
10
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
Zotero 插件